2025/03/25 更新

写真a

モリ　ショウイチロウ
森　章一郎
MORI Shoichiro
所属
医学部附属病院 皮膚科 助教
職名
助教

学位 2

  1. 学士(医学） （ 2013年4月   名古屋大学 ） 

  2. 学士 （ 名古屋大学 ） 

学位の先頭へ▲

経歴 1

  1. 名古屋大学   医学部皮膚科   病院助教

    2021年4月

経歴の先頭へ▲

学歴 1

  1. 名古屋大学   医学部   医学科

    2007年4月 - 2013年3月

学歴の先頭へ▲

所属学協会 1

  1. 日本皮膚科学会

    2015年4月

所属学協会の先頭へ▲

受賞 1

  1. ポスター賞

    2023年8月   皮膚悪性腫瘍学会   悪性黒色腫に対する抗PD1抗体単独療法での、１回投与量／投与間隔が異なるレジメンと有害事象の相関の検討

    森　章一郎

    　詳細を見る

    受賞区分：国内学会・会議・シンポジウム等の賞 

    第39回日本皮膚悪性腫瘍学会学術大会のポスター賞

受賞の先頭へ▲
 

論文 15

  1. Infiltration of M2a macrophages is predominant in genital verruciform xanthoma Open Access

    Miyazaki, A; Taki, T; Mori, S; Yamada, M; Akiyama, M

    JOURNAL OF DERMATOLOGY   52 巻 ( 3 ) 頁： 556 - 558   2025年3月

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of Dermatology  

    DOI： 10.1111/1346-8138.17654

    Open Access

    Web of Science

    Scopus

    PubMed

  2. Combined PD-1 and CTLA-4 Blockade Increases the Risks of Multiple Pituitary Hormone Deficiency and Isolated Adrenocorticotropic Deficiency: A Prospective Study.

    Iwama S, Kobayashi T, Izuchi T, Suzuki K, Murase T, Ando M, Handa T, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Mori S, Sano T, Akamatsu S, Akiyama M, Ishii M, Arima H

    Endocrinology and metabolism (Seoul, Korea)     2025年2月

    　詳細を見る

    記述言語：英語  

    DOI： 10.3803/EnM.2024.2180

    PubMed

  3. Prognostic value of the CONUT score with immune checkpoint inhibitors as first-line therapy for metastatic malignant melanoma

    Horisaki, K; Yoshikawa, S; Mori, S; Omata, W; Tsutsumida, A; Kiyohara, Y

    JOURNAL OF DERMATOLOGY     2025年2月

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of Dermatology  

    The recent availability of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced malignant melanoma (MM). However, many patients with MM do not benefit from ICI treatment. As immunotherapy is associated with significant toxicity and high treatment costs despite its excellent efficacy, it is pertinent to select patients who are likely to respond to ICIs. In this single-center, retrospective study we investigated whether the controlling nutritional status (CONUT) score is a useful prognostic marker in Japanese patients with advanced-stage cancer. We analyzed 123 patients with stage IV MM treated with ICIs as first-line systemic treatment at our hospital between February 2012 and July 2024. Receiver operating characteristic curve analysis was used to calculate the CONUT cut-off value and CONUT into two groups of ≥3 and ≤2. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan–Meier method, and differences in survival were assessed using the log-rank test. The Cox proportional hazard regression model was used to evaluate independent prognostic factors. Objective response rate (ORR), PFS, and OS were significantly low in the CONUT ≥3 group, characterized by low nutritional status and high inflammation. Multivariate analysis identified the CONUT score as an independent prognostic factor for both PFS and OS. The CONUT score was not significantly associated with the development of serious immune-related adverse events. The simplicity of the CONUT score may aid in identifying patients with MM who are suitable candidates for ICI treatment.

    DOI： 10.1111/1346-8138.17613

    Web of Science

    Scopus

    PubMed

  4. Protruding nodular fasciitis on the face

    Akanabe, H; Tanahashi, K; Mori, S; Murakami, Y; Motoi, T; Akiyama, M

    JOURNAL OF DERMATOLOGY     2024年12月

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of Dermatology  

    DOI： 10.1111/1346-8138.17591

    Web of Science

    Scopus

    PubMed

  5. A Case of Advanced Extramammary Paget's Disease With a High Tumor Mutation Burden That Showed Partial Lymph Node Regression With Pembrolizumab.

    Horisaki K, Taki T, Mori S, Okumura M, Akiyama M

    Cureus   16 巻 ( 10 ) 頁： e72592   2024年10月

    　詳細を見る

    記述言語：英語  

    DOI： 10.7759/cureus.72592

    PubMed

  6. Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective study Open Access

    Kobayashi, T; Iwama, S; Yamagami, A; Izuchi, T; Suzuki, K; Otake, K; Yasuda, Y; Ando, M; Onoue, T; Miyata, T; Sugiyama, M; Hagiwara, D; Suga, H; Banno, R; Hase, T; Nishio, N; Mori, S; Shimokata, T; Sano, T; Niimi, K; Yoshikawa, N; Akamatsu, S; Ando, Y; Akiyama, M; Sone, M; Ishii, M; Arima, H

    CANCER IMMUNOLOGY IMMUNOTHERAPY   73 巻 ( 8 ) 頁： 146   2024年6月

    　詳細を見る

    記述言語：英語   出版者・発行元：Cancer Immunology, Immunotherapy  

    Background: Anti-programmed cell death-1 (ligand-1) antibody [PD-(L)1-Ab] can cause destructive thyroiditis and/or hypothyroidism. In addition, tyrosine kinase inhibitors (TKIs) frequently induce hypothyroidism. The aim of this prospective study is to examine the incidence and clinical characteristics of thyroid dysfunction induced by combination therapy of a PD-(L)1-Ab and TKI [PD-(L)1-Ab/TKI]. Methods: A total of 757 patients treated with PD-(L)1-Ab or PD-(L)1-Ab/TKI were evaluated for anti-thyroid antibodies (ATAs) at baseline and for thyroid function for 48 weeks after treatment initiation and then observed until the last visit. Results: The cumulative incidences of destructive thyroiditis [4/23 (17.4%) vs. 45/734 (6.1%) patients, p < 0.001], isolated hypothyroidism [10/23 (43.5%) vs. 29/734 (4.0%) patients, p < 0.001], and all thyroid dysfunction [14/23 (60.9%) vs. 74/734 (10.1%) patients, p < 0.001] were significantly higher in the PD-(L)1-Ab/TKI group than PD-(L)1-Ab group, respectively. All patients positive for ATAs at baseline developed thyroid dysfunction after PD-(L)1-Ab/TKI treatment, a significantly higher incidence than that in those negative for ATAs at baseline [4/4 (100%) vs. 10/19 (52.6%) patients, p = 0.026]. Conclusions: The addition of TKIs increased the risk of thyroid dysfunction induced by PD-(L)1-Ab, with the risk being higher in patients positive for baseline ATAs.

    DOI： 10.1007/s00262-024-03733-2

    Open Access

    Web of Science

    Scopus

    PubMed

  7. Lentigo maligna melanoma showing radial growth mimicking eruptive melanocytic nevi Open Access

    Miyazaki, A; Taki, T; Mori, S; Yamada, M; Akiyama, M

    DERMATOLOGICA SINICA   42 巻 ( 2 ) 頁： 162 - 163   2024年4月

    　詳細を見る

    出版者・発行元：Dermatologica Sinica  

    DOI： 10.4103/ds.DS-D-23-00131

    Open Access

    Web of Science

    Scopus

  8. Acquired reactive perforating collagenosis and eosinophilic granulomatosis with polyangiitis developing simultaneously in a diabetic patient

    Miyazaki, A; Taki, T; Mori, S; Fujishiro, R; Arai, Y; Yamada, M; Akiyama, M

    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY   7 巻   2024年2月

    　詳細を見る

  9. 特集 毛包系腫瘍 臨床例 FDG-PET/CTで両腋窩リンパ節に偽陽性を示した増殖性外毛根鞘性腫瘍

    森 章一郎, 山田 元人

    皮膚病診療   46 巻 ( 2 ) 頁： 177 - 181   2024年2月

    　詳細を見る

    出版者・発行元：協和企画  

    DOI： 10.24733/pd.0000003735

    CiNii Research

  10. Low plasma fibrinogen levels are associated with poor prognosis in cutaneous angiosarcoma of the head and neck

    Taki, T; Mori, S; Murakami, Y; Urata, T; Okumura, M; Akanabe, H; Ebata, A; Imai, S; Yokota, K; Akiyama, M

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   142 巻 ( 12 ) 頁： S265 - S265   2022年12月

    　詳細を見る

  11. 切除断端確保に難渋した頭頂部隆起性皮膚線維肉腫の1例

    茜部 穂波, 森 章一郎, 奥村 真央, 浦田 透, 村上 佳恵, 横田 憲二, 秋山 真志, 棚橋 邦明, 蛯沢 克己, 森 誉子

    Ｓｋｉｎ　Ｃａｎｃｅｒ   37 巻 ( 3 ) 頁： 213 - 217   2022年

    　詳細を見る

    記述言語：日本語   出版者・発行元：日本皮膚悪性腫瘍学会  

    <p>20歳，男性。2020年1月頃より頭皮に結節を自覚した。徐々に増大し同年3月に前医を受診した。生検で悪性間葉系腫瘍を疑われ当科紹介となった。初診時，頭頂部に可動性不良な5×3cm大の隆起性紅色結節を認めた。再生検した所紡錘形細胞の増殖を認め，CD34陽性であり，他院で行った遺伝子検査で<i>COL1A1－PDGFB</i>融合遺伝子を認めたため，線維肉腫様変化を伴う隆起性皮膚線維肉腫と診断した。CTで遠隔転移を認めず，結節近傍の皮下にも結節を認めた。MRIで頭蓋骨骨膜へ癒着があり骨膜浸潤が疑われた。病変周囲を20mmマージンでマッピング生検し1ヵ所陽性。陽性部からさらに10mm離して生検したが再度陽性。さらに10mm離して生検し陰性を得た。生検結果を参考に頭蓋骨を含め広範囲切除，人工骨挿入し遊離広背筋皮弁および分層植皮で再建した。術後病理検査で切除断端は陰性，術後20ヵ月再発はない。頭部隆起性皮膚線維肉腫の切除範囲の決定にマッピング生検が有用な可能性がある。</p>

    DOI： 10.5227/skincancer.37.213

    CiNii Research

  12. Neutrophil/lymphocyte ratio as a predictor of lymph node metastasis in extramammary Paget disease: A retrospective study

    Ebata, A; Taki, T; Mori, S; Murakami, Y; Urata, T; Okumura, M; Akanabe, H; Imai, S; Yokota, K; Akiyama, M

    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY   85 巻 ( 4 ) 頁： 1023 - 1025   2021年10月

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of the American Academy of Dermatology  

    DOI： 10.1016/j.jaad.2020.12.087

    Web of Science

    Scopus

    PubMed

  13. Neutrophil/lymphocyte ratio as a predictor of lymph node metastasis in extramammary Paget disease: A retrospective study

    Ebata, A; Taki, T; Mori, S; Murakami, Y; Okumura, M; Akanabe, H; Imai, S; Yokota, K; Akiyama, M

    JOURNAL OF INVESTIGATIVE DERMATOLOGY   141 巻 ( 10 ) 頁： S197 - S197   2021年10月

    　詳細を見る

  14. Low plasma fibrinogen levels are associated with poor prognosis in cutaneous angiosarcoma of the head and neck Open Access

    Mori, S; Taki, T; Murakami, Y; Urata, T; Okumura, M; Akanabe, H; Ebata, A; Imai, S; Yokota, K; Akiyama, M

    CANCER SCIENCE   112 巻 ( 9 ) 頁： 3924 - 3927   2021年9月

    　詳細を見る

    記述言語：英語   出版者・発行元：Cancer Science  

    DOI： 10.1111/cas.15037

    Web of Science

    Scopus

    PubMed

  15. Cutaneous malignant melanoma in an elderly patient with intermediate junctional epidermolysis bullosa

    Yamashita, Y; Taki, T; Takeichi, T; Okumura, M; Mori, S; Ito, Y; Ogi, T; Yamada, M; Akiyama, M

    JOURNAL OF DERMATOLOGY   48 巻 ( 8 ) 頁： E384 - E385   2021年8月

    　詳細を見る

    記述言語：英語   出版者・発行元：Journal of Dermatology  

    DOI： 10.1111/1346-8138.15951

    Web of Science

    Scopus

    PubMed

▼全件表示

論文の先頭へ▲